199 related articles for article (PubMed ID: 38159950)
1. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
[TBL] [Abstract][Full Text] [Related]
3. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches.
Bach SP;
Colorectal Dis; 2022 May; 24(5):639-651. PubMed ID: 35114057
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).
Sun Myint A; Rao C; Barbet N; Thamphya B; Pace-Loscos T; Schiappa R; Magné N; Martel-Lafay I; Mineur L; Deberne M; Zilli T; Dhadda A; Gerard JP
Colorectal Dis; 2023 Nov; 25(11):2160-2169. PubMed ID: 37837240
[TBL] [Abstract][Full Text] [Related]
5. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
[TBL] [Abstract][Full Text] [Related]
6. Can we
Rombouts AJM; Al-Najami I; Abbott NL; Appelt A; Baatrup G; Bach S; Bhangu A; Garm Spindler KL; Gray R; Handley K; Kaur M; Kerkhof E; Kronborg CJ; Magill L; Marijnen CAM; Nagtegaal ID; Nyvang L; Peters FP; Pfeiffer P; Punt C; Quirke P; Sebag-Montefiore D; Teo M; West N; de Wilt JHW;
BMJ Open; 2017 Dec; 7(12):e019474. PubMed ID: 29288190
[TBL] [Abstract][Full Text] [Related]
7. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
8. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
9. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
10. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y
BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233
[TBL] [Abstract][Full Text] [Related]
12. STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.
Bach SP
Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e107-e109. PubMed ID: 36577551
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II).
PelvEx Collaborative
BJS Open; 2021 May; 5(3):. PubMed ID: 34089596
[TBL] [Abstract][Full Text] [Related]
15. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
[TBL] [Abstract][Full Text] [Related]
16. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
17. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
18. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
19. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
[No Abstract] [Full Text] [Related]
20. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
